ArticleCellular and molecular bioengineering2019
Ultrasound Enhanced Anti-tumor Effect of Temozolomide in Glioblastoma Cells and Glioblastoma Mouse Model.
Article in Cellular and molecular bioengineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- MiR-760 exerts a critical regulatory role in glioma proliferation, migration, and invasion by modulating MMP2 expression.Journal of Cancer · 2024Article
- Drug resistance in glioblastoma: from chemo- to immunotherapy.Cancer drug resistance (Alhambra, Calif.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlioblastoma is the most aggressive cancer that begins within the brain. In clinic, temozolomide was used as anti-tumor drugs for glioblastoma chemotherapy, but showed limited effect. Therefore, how to improve the effect of temozolomide to glioblastoma is urgently needed.
methodsThe cell viability of T98G cells was detected by cell counting kit-8 (CCK-8) assay. Apoptosis was detected using the Annexin-V-FITC & PI apoptosis kit and assessed by flow cytometry. The expression levels of Bax, B cell lymphoma 2 (Bcl-2), phos-Jun N-terminal kinases (JNK), phos-extracellular signal-regulated kinases (ERK) and phos-p38 were determined by western blot. The effect of ultrasound and temozolomide combination in mice was determined by survival analysis.
resultsCompared with temozolomide treatment alone, ultrasound and temozolomide combination inhibited the cell viability, and promotes apoptosis of human glioblastoma T98G cells. Bax level increased, while Bcl-2 level decreased in combination group. Mechanically, combination treatment promoted apoptosis
conclusionsUltrasound enhanced anti-tumor effect of temozolomide in glioblastoma cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.